Table 3.

Meta-analysis of the different patients’ characteristics and underlying conditions and the risk of development of severe/critical COVID-19.

Condition	Study	Number of Primary Studies	Odds Ratio	IC 95%
Male sex	Dorjee et al.	77	1.30	1.21–1.42
Smoking history	Dorjee et al.	77	1.28	1.06–1.55
Obesity	Zhou et al.	34	1.72	1.04–2.85
	Kumar et al.	22	2.84	1.19–6.77
	pOR	56	1.95	1.26–3.02
Malignancy	Zhou et al.	34	2.73	1.73–4.21
	Ssentongo et al.	25	1.47	1.01–2.14
	Kumar et al.	22	2.38	1.25–4.52
	Li et al.	12	2.21	1.04–4.72
	Giri et al.	41	1.75	1.40–2.18
	pOR	134	1.91	1.54–2.37
Chronic renal disease	Dorjee et al.	77	2.5	2.09–2.99
	Zhou et al.	34	3.02	2.23–4.08
	Ssentongo et al.	25	3.25	1.13–9.28
	Kumar et al.	22	1.46	1.06–2.02
	Fernadez et al.	74	2.5	1.82–3.44
	pOR	232	2.35	1.83–3.03
Chronic liver disease	Dorjee et al.	77	2.65	1.88–3.75
	Zhou et al.	34	1.54	0.95–2.49
	Yin et al.	41	1.32	0.96–1.82
	pOR	115	1.76	1.12–2.78
Diabetes mellitus	Dorjee et al.	77	1.5	1.36–1.65
	Zhou et al.	34	2.63	2.08–3.33
	Ssentongo et al.	25	1.82	1.43–2.23
	Kumar et al.	22	2.29	1.56–3.39
	Li et al.	12	3.17	2.26–4.45
	Giri et al.	41	2.04	1.67–2.50
	pOR	211	2.13	1.68–2.70
Chronic pulmonary disease	Dorjee et al.	77	1.7	1.4–2.0
	Zhou et al.	34	3.56	2.87–4.41
	Yang et al.	7	2.46	1.76–3.44
	Kumar et al.	22	2.92	1.70–5.02
	Li et al.	12	5.08	2.68–9.63
	pOR	152	2.82	1.92–4.14
Cardiovascular disease	Dorjee et al.	77	2.1	1.82–2.43
	Zhou et al.	34	3.13	2.65–3.70
	Ssentongo et al.	25	2.25	1.60–3.17
	Kumar et al.	22	1.61	1.31–1.98
	Li et al.	12	2.66	1.71–4.15
	Giri et al.	41	2.78	2.00–3.86
	Fernández et al.	34	3.20	2.29–4.48
	pOR	245	2.44	1.97–3.01
Cerebrovascular disease	Zhou et al.	34	2.74	1.59–4.74

pOR: pooled odds ratio of included studies for each condition.